the effect of rituximab in ttp patient refractory to plasmexchange

efficacy of rituximab in treatmeantof plasma exchange refractory TTP

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017012232125N1

Enrollment

Registered

2017-07-25

Start date

2010-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TTP. .thrombotic thrombocytopenic purpura

Interventions

TTP patients that rule out secondary cause undergo treatmeant with monoclonal anti body (Rituximab) . this drug is anti CD20 ,marcker on the B Lymphocyte . Rituximab dose was 375 mg/m2 weekly for 4 we

Treatment - Drugs

TTP patients that rule out secondary cause undergo treatmeant with monoclonal anti body (Rituximab) . this drug is anti CD20 ,marcker on the B Lymphocyte . Rituximab dose was 375 mg/m2 weekly for 4 w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: exclusion:viral infection, malignancy,autoimmune disease,drug(cyclosporine,ticlopidine,..) inclusion:criteria for ttp diagnosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
PLT-LDH. Timepoint: daily check to recieve to goal of treatmeant. Method of measurement: laboratory.	—

Secondary

Measure	Time frame
BUN CR. Timepoint: at first daily check then weekly and monthly. Method of measurement: laboratory.;Level of consciousness. Timepoint: at first daily check then weekly and monthly. Method of measurement: clinical examination.;Drug complication. Timepoint: at first daily check then weekly and monthly. Method of measurement: clinical examination- laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactali reza sadeghi MD

ESFAHAN UNIVERSITY OF MEDICINE

sadeghi_hem@yahoo.com+98 31 3673 3910

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026